Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

By Q. Gao, Xiao-Ying Wang, S. Qiu, I. Yamato, M. Sho, Y. Nakajima, Jian Zhou, Bai-zhou Li, Yinghong Shi, Yong-Sheng Xiao and 2 more. Clinical Cancer Research, 2009

779 citations recorded by the source corpus.

Subfields: Hepatology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/235d100720634094de0baa6ef17381726aa7705d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. B. Sangro

In Oncology

1. I. Mellman
2. Padmanee Sharma
3. Xu Dong Zhang
4. I. Melero
5. Lei Jin
6. George Coukos
7. G. Dranoff
8. Jiezhong Chen

Citations in the corpus

• Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”
• PD-L1 Expression in Triple Negative Breast Cancer (2014, positive): “PD-L1 is not expressed on normal epithelial tissues but is expressed on many cancers including renal cell carcinoma (20, 26), pancreatic cancer (27), ovarian cancer (28), gastric cancer (29), esophageal cancer (30), and hepatocellular carcinoma (31).”
• Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. (2016, neutral): “PD-L1expressionhasbeenassociated with exposure to interferon-g (IFN-g; e.g., after anti-tumor Th1 cell responses; Dong et al., 2002; Gao et al., 2009) and providesanefficientmeans for tumorcells toevadeTcell immunosurveillance.”
• Cancer immunotherapy comes of age (2011, positive): “PD-L1 expression has been found to correlate with poor prognosi”
• Regulation of PD-L1: a novel role of pro-survival signalling in cancer. (2016, background): “The potential practical implications of the interaction between pro-survival signalling pathways and the immune system will also be deliberated. the PD-1/PD-L1 axis Well-orchestrated T-cell activation is necessary for defending the host against pathogens and preventing autoimmune responses.”
• Macrophages in Tumor Microenvironments and the Progression of Tumors (2012, background): “Recently, it was reported that an anti-PD-L1 antibody, which blocks the PD-1/PD-L1 pathway, can improve macrophagemediated T-cell activation in HCC in vivo and has progressed to a phase I clinical study [121, 122].”